Get the Stockscreener App
20.39
3.86%
-0.75
Sarepta Therapeutics Inc stock is traded at $20.39, with a volume of 1.59M.
It is down -3.86% in the last 24 hours and up +16.54% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$21.14
Open:
$21.15
24h Volume:
1.59M
Relative Volume:
0.31
Market Cap:
$2.14B
Revenue:
$2.48B
Net Income/Loss:
$-57.96M
P/E Ratio:
-26.88
EPS:
-0.7585
Net Cash Flow:
$-453.97M
1W Performance:
-6.56%
1M Performance:
+16.54%
6M Performance:
-2.15%
1Y Performance:
-83.10%
1-Day Range:
$20.14
$21.64
1-Week Range:
$20.14
$22.97
52-Week Range:
$10.41
$129.84
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
20.40 | 2.22B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.40 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.13 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.63 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.49 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.64 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance
Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда
Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP) - Sarepta Therapeutics
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Argenx Se (ARGX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.3%Still a Buy? - MarketBeat
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025 - ts2.tech
Why Sarepta Therapeutics Stock is Gaining Attention - TipRanks
Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screeni - GuruFocus
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. - CBS News
683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat
Sarepta Therapeutics Refinances Convertible Senior Notes - The Globe and Mail
Sarepta CEO given first equity award in 8 years - The Business Journals
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Sarepta Therapeutics refinances convertible senior notes - MSN
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing - Investing.com
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing By Investing.com - Investing.com UK
Sarepta Therapeutics stock falls after debt exchange announcement By Investing.com - Investing.com South Africa
Sarepta Therapeutics stock falls after debt exchange announcement - Investing.com
Why Is SRPT Stock Falling Today? - Stocktwits
Sector Update: Health Care Stocks Mixed Premarket Thursday - marketscreener.com
Sarepta dips after announcing debt refinancing - TradingView
Sarepta Therapeutics stock falls after refinancing of convertible notes By Investing.com - Investing.com South Africa
Sarepta Therapeutics stock falls after refinancing of convertible notes - Investing.com
Sarepta to refinance $291M of existing notes due 2027 - MSN
Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027 - marketscreener.com
Sarepta Therapeutics announces refinancing of approximately $291 million of 1.25% convertible senior notes due 2027 - marketscreener.com
Sarepta Therapeutics Announces Refinancing Of Approximately $291 Million Of 1.25% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Sarepta to exchange $291.4 million in convertible notes - Investing.com
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire
CFO Wong Surrenders 158 Of Sarepta Therapeutics Inc [SRPT] - TradingView — Track All Markets
Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc. - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements - Kalkine Media
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound - Yahoo Finance
Is Sarepta Therapeutics a Bargain After Recent Share Rebound and DCF Valuation Check? - Yahoo Finance
Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off - Finimize
Wedbush Says Sarepta Selloff “Overdone” - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpWhat's Next? - MarketBeat
Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says - marketscreener.com
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential - GuruFocus
Sarepta a new outperform at Wedbush as selloff overdone - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush - MarketBeat
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT S - GuruFocus
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):